{"id":696,"date":"2012-10-22T11:10:29","date_gmt":"2012-10-22T11:10:29","guid":{"rendered":"https:\/\/blogs.bmj.com\/spcare\/?p=696"},"modified":"2012-10-22T11:10:29","modified_gmt":"2012-10-22T11:10:29","slug":"news-and-updates-from-www-palliativedrugs-com-30","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/spcare\/2012\/10\/22\/news-and-updates-from-www-palliativedrugs-com-30\/","title":{"rendered":"News and updates from www.palliativedrugs.com"},"content":{"rendered":"<p><strong><em>Selected items from the News and Latest Additions sections of <a href=\"http:\/\/www.palliativedrugs.com\/\">www.palliativedrugs.com<\/a>, the world\u2019s leading palliative care website.<\/em><\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Drug updates<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Ketamine injection supply problems<\/strong><\/p>\n<p>Pfizer UK has confirmed that there is a supply problem with ketamine (Ketalar) 10mg\/mL and 100mg\/mL injection. All orders for these products are now being re-directed to a Pfizer central ordering point (0845 608866), to allow close monitoring of the stock situation. It is anticipated that the 100mg\/mL injection will run out completely in September 2012 and will not be available until November 2014. Pfizer has stated that this situation has occurred due to a transfer of the manufacturing site which was beyond their control. More ketamine 10mg\/mL injection are being manufactured as an interim measure. The stock situation of ketamine 50mg\/mL is currently sufficient but is being monitored. For further details please contact Pfizer customer services (01304 606161).<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Oxycodone m\/r generic launched in UK<\/strong><\/p>\n<p>Qdem Pharmaceuticals (Cambridge, UK) have launched generic oxycodone m\/r (Longtec prolonged release) 5mg, 10mg, 20mg, 40mg and 80mg tablets. Supplies will come from Bard Pharmaceuticals, the production and supply chain business of Napp, and will be available through the usual wholesalers. The NHS cost and product range comparison with Oxycontin m\/r (Napp) is:<\/p>\n<p>&nbsp;<\/p>\n<p>Longtec (Qdem)<\/p>\n<p><strong><em>Tablets m\/r<\/em><\/strong> 5mg, 10mg, 20mg, 40mg and 80mg, 28 days @ 1 tablet b.d.= \u00a321, \u00a321, \u00a342, \u00a385, and \u00a3170 respectively.<\/p>\n<p>&nbsp;<\/p>\n<p>Oxycontin (Napp)<\/p>\n<p><strong><em>Tablets m\/r<\/em><\/strong> 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg and 120mg, 28 days @ 1 tablet b.d. = \u00a325, \u00a325, \u00a337, \u00a350, \u00a375, \u00a3100, \u00a3150, \u00a3200 and \u00a3300 respectively.<\/p>\n<p>&nbsp;<\/p>\n<p>Note: The remains of the m\/r tablet may appear in the patient\u2019s faeces (\u2018ghost tablets\u2019), as can also occur with Oxycontin and Targinact (oxycodone\/naloxone combined m\/r tablet). These are inert residues, and do not affect the efficacy of the products.<\/p>\n<p>For more information click <span style=\"text-decoration: underline\"><a href=\"http:\/\/www.medicines.org.uk\/emc\/medicine\/26598\/SPC\/\">here<\/a><\/span>.<\/p>\n<p><strong><span style=\"text-decoration: underline\">\u00a0<\/span><\/strong><\/p>\n<p><strong>Epistatus product description change<\/strong><\/p>\n<p>There has been a change made to the product description of the unauthorized (unlicensed) midazolam product Epistatus (Special Products Limited; Weybridge, Surrey, UK) as follows:<\/p>\n<p>&nbsp;<\/p>\n<p>Midazolam (Epistatus) 10mg in 1mL Buccal Liquid x 5mL<\/p>\n<p><em>has been replaced with<\/em><em><\/em><\/p>\n<p>Midazolam (Epistatus) 10mg in 1mL Oromucosal Solution x 5mL.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Paracetamol overdose: new guidance on treatment<\/strong><\/p>\n<p>New simplified guidance on the treatment of acute paracetamol overdose with acetylcysteine is now in place following an evidence-based review by the Commission on Human Medicines in the UK. Full details can be found in the Medicines and Healthcare products Regulatory Agency (MHRA) September 2012 <span style=\"text-decoration: underline\"><a href=\"http:\/\/www.mhra.gov.uk\/\/Safetyinformation\/DrugSafetyUpdate\/CON185624\">Drug Safety Update<\/a><\/span>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Batch recall of Lyrica 50mg capsules (Kosei Pharma)<\/strong><\/p>\n<p>A company-led recall of a batch of Lyrica (pregabalin) hard capsules 50mg (parallel distributed in the UK by Kosei Pharma Limited) has been issued, as the label applied by the parallel distributor states the strength as 25mg instead of 50mg. It is understood that a very small number of units have been distributed. The affected batch number is 0605032P\/2 (first distributed 7<sup>th<\/sup> September 2012; expiry date February 2015). For further information contact Kosei Pharma UK Customer Services (01753 569528) or click <span style=\"text-decoration: underline\"><a href=\"http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/DrugAlerts\/Company-ledrecalls\/CON185171\">here<\/a><\/span>.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>Prepared by Sarah Charlesworth and Andrew Wilcock<\/em><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world\u2019s leading palliative care website. &nbsp; Drug updates &nbsp; Ketamine injection supply problems Pfizer UK has confirmed that there is a supply problem with ketamine (Ketalar) 10mg\/mL and 100mg\/mL injection. All orders for these products are now being re-directed to a Pfizer central [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/spcare\/2012\/10\/22\/news-and-updates-from-www-palliativedrugs-com-30\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":157,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2833],"tags":[],"class_list":["post-696","post","type-post","status-publish","format-standard","hentry","category-updates-from-www-palliativedrugs-com"],"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/users\/157"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/comments?post=696"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/696\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/media?parent=696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/categories?post=696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/tags?post=696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}